{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Microsatellite+Stable+Colorectal+Cancer", "query": { "condition": "Metastatic Microsatellite Stable Colorectal Cancer" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 64, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Microsatellite+Stable+Colorectal+Cancer&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T04:02:28.533Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07147231", "title": "Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Colorectal Adenocarcinoma", "Refractory Colorectal Adenocarcinoma", "Stage III Colorectal Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Unresectable Colorectal Adenocarcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pidnarulex", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 86, "start_date": "2026-12-21", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-05-22T04:02:28.533Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07147231" }, { "nct_id": "NCT05572684", "title": "A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced or Metastatic Solid Tumors", "Microsatellite Instability Low", "Microsatellite Instability High", "Microsatellite Stable", "Ovarian Cancer", "Gastric Cancer", "Colo-rectal Cancer", "Esophageal Cancer", "Endometrial Cancer", "Head Neck Cancer", "Cervical Cancer", "Lung Cancer" ], "interventions": [ { "name": "NC410", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NextCure, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 97, "start_date": "2022-10-06", "completion_date": "2025-11", "has_results": false, "last_update_posted_date": "2024-12-16", "last_synced_at": "2026-05-22T04:02:28.533Z", "location_count": 17, "location_summary": "Tucson, Arizona • Aurora, Colorado • Edgewood, Kentucky + 11 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Edgewood", "state": "Kentucky" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05572684" }, { "nct_id": "NCT05167409", "title": "A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Microsatellite Stable Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Evorpacept (ALX148)", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2022-07-28", "completion_date": "2026-03-01", "has_results": false, "last_update_posted_date": "2025-01-13", "last_synced_at": "2026-05-22T04:02:28.533Z", "location_count": 4, "location_summary": "Tucson, Arizona • Aurora, Colorado • New Brunswick, New Jersey + 1 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05167409" }, { "nct_id": "NCT05609370", "title": "A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer" ], "interventions": [ { "name": "LBL-007", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Bevacizumab or Bevacizumab biosimilar", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 113, "start_date": "2023-01-29", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2025-10-02", "last_synced_at": "2026-05-22T04:02:28.533Z", "location_count": 30, "location_summary": "Anchorage, Alaska • Gilbert, Arizona • Cerritos, California + 23 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Cerritos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05609370" }, { "nct_id": "NCT03983993", "title": "Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Microsatellite Stable Colorectal Carcinoma", "Metastatic Microsatellite Stable Colorectal Carcinoma", "Microsatellite Stable", "RAS Wild Type", "Stage IV Colorectal Cancer AJCC v8", "MSI-H Colorectal Cancer" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" }, { "name": "Panitumumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2019-10-15", "completion_date": "2026-12-01", "has_results": true, "last_update_posted_date": "2026-01-05", "last_synced_at": "2026-05-22T04:02:28.533Z", "location_count": 3, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03983993" }, { "nct_id": "NCT02060188", "title": "A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Microsatellite Unstable Colorectal Cancer", "Microsatellite Stable Colorectal Cancer", "Mismatch Repair Proficient Colorectal Cancer", "Mismatch Repair Deficient Colorectal Cancer" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "BMS-986016", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 385, "start_date": "2014-03-12", "completion_date": "2024-10-22", "has_results": true, "last_update_posted_date": "2025-11-06", "last_synced_at": "2026-05-22T04:02:28.533Z", "location_count": 14, "location_summary": "Gilbert, Arizona • Los Angeles, California • San Francisco, California + 10 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02060188" }, { "nct_id": "NCT03271047", "title": "Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "MSS", "RAS-mutant Colorectal Cancer" ], "interventions": [ { "name": "binimetinib", "type": "DRUG" }, { "name": "nivolumab", "type": "DRUG" }, { "name": "ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2017-10-18", "completion_date": "2021-02-25", "has_results": true, "last_update_posted_date": "2022-01-04", "last_synced_at": "2026-05-22T04:02:28.533Z", "location_count": 33, "location_summary": "Los Angeles, California • Santa Monica, California • Newark, Delaware + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Newark", "state": "Delaware" }, { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT03271047" }, { "nct_id": "NCT07079631", "title": "A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "BNT314", "type": "BIOLOGICAL" }, { "name": "BNT327", "type": "DRUG" }, { "name": "SoC chemotherapy treatment 1", "type": "DRUG" }, { "name": "SoC chemotherapy treatment 2", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 482, "start_date": "2025-07-18", "completion_date": "2031-05", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-05-22T04:02:28.533Z", "location_count": 4, "location_summary": "New Haven, Connecticut • Grand Rapids, Michigan • Cleveland, Ohio + 1 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07079631" }, { "nct_id": "NCT04362839", "title": "Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Colon Adenocarcinoma", "Metastatic Colon Adenocarcinoma", "Metastatic Colorectal Adenocarcinoma", "Metastatic Colorectal Carcinoma", "Metastatic Rectal Adenocarcinoma", "Stage III Colon Cancer AJCC v8", "Stage III Rectal Cancer AJCC v8", "Stage IIIA Colon Cancer AJCC v8", "Stage IIIA Rectal Cancer AJCC v8", "Stage IIIB Colon Cancer AJCC v8", "Stage IIIB Rectal Cancer AJCC v8", "Stage IIIC Colon Cancer AJCC v8", "Stage IIIC Rectal Cancer AJCC v8", "Stage IV Colon Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Rectal Cancer AJCC v8", "Stage IVA Colon Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVA Rectal Cancer AJCC v8", "Stage IVB Colon Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVB Rectal Cancer AJCC v8", "Stage IVC Colon Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8", "Stage IVC Rectal Cancer AJCC v8" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Regorafenib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2020-05-27", "completion_date": "2025-12-11", "has_results": false, "last_update_posted_date": "2026-01-28", "last_synced_at": "2026-05-22T04:02:28.533Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04362839" }, { "nct_id": "NCT03189030", "title": "Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Neoplasms" ], "interventions": [ { "name": "pLADD", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Aduro Biotech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2017-05-02", "completion_date": "2020-09-02", "has_results": false, "last_update_posted_date": "2020-10-01", "last_synced_at": "2026-05-22T04:02:28.533Z", "location_count": 5, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03189030" } ] }